CINCINNATI--(BUSINESS WIRE)--Jul. 7, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced today that FORTUNE Small Business has ranked Meridian Bioscience, Inc. number 34 on their ninth annual FSB 100 list of the fastest growing small public companies in America. The list appears in the July/August issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2009/.

To compile the ninth annual list, FORTUNE Small Business asked financial research firm Zacks to rank public companies with revenues less than $200 million and a stock price of more than $1 by their three-year annualized rate of revenue growth and return to investors.

John A. Kraeutler, Chief Executive Officer, stated, "For the fifth year in a row Meridian Bioscience has been ranked among the top 100 fastest growing companies by FORTUNE Small Business magazine. This acknowledgement is sincerely appreciated. Our performance in delivering shareholder value, while helping improve the diagnosis of disease, is directly due to our outstanding employees and our valuable customers around the globe."

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Source: Meridian Bioscience, Inc.

Meridian Bioscience, Inc.
John A. Kraeutler, CEO, 513-271-3700